WO2006088080A1 - シクロヘプタ[b]ピリジン-3-カルボニルグアニジン誘導体およびそれを含有する医薬品 - Google Patents
シクロヘプタ[b]ピリジン-3-カルボニルグアニジン誘導体およびそれを含有する医薬品 Download PDFInfo
- Publication number
- WO2006088080A1 WO2006088080A1 PCT/JP2006/302713 JP2006302713W WO2006088080A1 WO 2006088080 A1 WO2006088080 A1 WO 2006088080A1 JP 2006302713 W JP2006302713 W JP 2006302713W WO 2006088080 A1 WO2006088080 A1 WO 2006088080A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyridine
- cyclohepta
- compound
- tetrahydro
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Definitions
- the present invention relates to a pharmaceutical, particularly to a novel cyclohepta [b] pyridine 3-carbonyldazine derivative having an inhibitory action on Na + ZH + exchange transporter (NHE) and a pharmaceutical containing the same.
- NHE Na + ZH + exchange transporter
- NHE in the cell membrane is an ion transporter that regulates intracellular ⁇ by influxing Na T into the cell and pumping PT out of the cell.
- Ca 2+ overload during ischemia reperfusion is It is thought to be caused by increased NHE activity. Therefore, NHE inhibitor suppresses the Ca 2 + overload, is believed to inhibit the expansion of suppression and myocardial necrosis ventricular fibrillation by reperfusion arrhythmias.
- NHE is an ischemia or ischemia reperfusion injury in various organs such as brain, liver and kidney other than the heart, diseases caused by hypertension, angina pectoris, cardiac hypertrophy, diabetes, cell proliferation, vascular endothelium The involvement of the disorder in the disease has also been suggested. Therefore, NHE inhibitors are expected to be effective in suppressing these diseases and are considered useful as therapeutic or preventive drugs.
- the K + -retaining diuretic amyloride represented by the following formula is a virazine derivative having acyl guanidine, which has been reported to have an NHE inhibitory action and an antiarrhythmic action (non-patented). Reference 1).
- the antiarrhythmic action of Amiguchi Ride has a weakening action and a pressure reducing action and a salt excretion action, which are undesirable side effects for the treatment of arrhythmia. Has become
- Non-patent Documents 2, 1 and 2 Indoylguanine derivatives (Patent Documents) that have NHE inhibitory activity without salt excretion and show antiarrhythmic activity 3) Aminoguanidine hydrazine derivatives (Patent Document 4) and cycloal [b] pyridine derivatives (Patent Document 5) have been reported.
- Non-patent Document 3 In recent years, it has been reported that NHE inhibitors, when passing through the blood-brain barrier and reaching the brain, exhibit specific neurotoxicity common to specific sites. In addition, strong ataxia and neuropathy specific to the cerebellum, vestibular nucleus, and cochlear nucleus have been reported in mice lacking the NHE1 gene (Non-patent Document 4). Such neurotoxicity can cause various neurological disorders. Therefore, development of NHE inhibitors that do not affect nerve cells is desired.
- Patent Document 6 as a method for reducing the action on the nervous system, particularly the central nervous system, SO H groups (sulfo groups), PO H groups, etc. are added to existing NHE inhibitors via various crosslinking groups.
- the present inventors synthesized and studied various compounds, and depending on the combination of the substituent and the NHE inhibitor serving as the mother nucleus, the NHE inhibitory effect is greatly attenuated, or degradation and metabolism are performed immediately after administration.
- the NHE inhibitory effect is greatly attenuated, or degradation and metabolism are performed immediately after administration.
- it was not always effective in reducing the toxic effects of the central nervous system because it was converted to the original NHE inhibitor, or the derivative itself showed an effect on the central nervous system.
- Patent Document 1 Japanese Patent Laid-Open No. 05-339228
- Patent Document 2 JP 08-0773427 A Patent Document 3: Japanese Patent Laid-Open No. 08-208602
- Patent Document 4 Japanese Patent Laid-Open No. 2000-191641
- Patent Document 5 Pamphlet of International Publication No. 98Z39300
- Patent Document 6 International Publication No. 01Z044186 Pamphlet
- Non-Patent Document 1 Circulation, 1989, 79 ⁇ , p. 1257—126 3
- Non-Patent Document 2 Journal ⁇ Ob ⁇ Molecular ⁇ ⁇ ⁇ Journal of molecular cell cardiology, 1992, 24 ⁇ (suppl. 1), S. 92
- Non-Patent Document 3 European Journal of Pharmacology, 2003, 459 ⁇ , p. 151—158
- Non-Patent Document 4 Cell, 1997, 91 ⁇ , p. 139-148
- An object of the present invention is to provide a low molecular weight compound useful as a pharmaceutical having an inhibitory action on NHE and reduced toxic action on the central nervous system.
- the present invention relates to the general formula (1)
- R 1 is a sulfo group, a sulfoxy group, OCONH— (CH 2 CH 2 O) —SO 2 H and
- R 2 represents a halogen atom, a lower alkyl group or a lower alkoxy group, and ⁇ represents an integer of 1 to 10.
- the present invention relates to a cyclohepta [b] pyridine 3-carbo-guanidine derivative represented by the formula (1) or a pharmaceutically acceptable salt thereof, and a medicine containing the same.
- the present invention also includes a cyclohepta [b] pyridine 3 carbonyldazazine derivative represented by the above general formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- a pharmaceutical composition is provided.
- the present invention also provides use of the cyclohepta [b] pyridine 3 carbonyldazazine derivative represented by the above general formula (1) or a pharmaceutically acceptable salt thereof for pharmaceutical production. is there.
- the present invention provides a hypertension characterized by administering a cyclohepta [b] pyridine-3-sulphonyldazine derivative represented by the above general formula (1) or a pharmaceutically acceptable salt thereof.
- a hypertension characterized by administering a cyclohepta [b] pyridine-3-sulphonyldazine derivative represented by the above general formula (1) or a pharmaceutically acceptable salt thereof.
- Treatment of diseases caused by dysfunction, arrhythmia, angina pectoris, cardiac hypertrophy, diabetes, organ damage due to ischemia or ischemia-reperfusion, cerebral ischemic injury, cell hyperproliferation or vascular endothelial cells A method is provided.
- Cyclohepta [b] pyridine 3 carbonyl dial represented by the general formula (1) of the present invention Derivatives or pharmaceutically acceptable salts thereof show excellent NHE inhibitory action in vitro and in vivo, and have extremely low toxic effects on the central nervous system. Therefore, the cyclohepta [b] pyridine 3 carboguanidine derivative represented by the general formula (1) of the present invention or a pharmaceutically acceptable salt thereof can be produced by various drugs, particularly when NHE is stimulated.
- R 2 represents a halogen atom, a lower alkyl group or a lower alkoxy group.
- halogen atom there can be mentioned a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
- the lower alkyl group include a straight chain or branched chain alkyl group having 1 to 6 carbon atoms such as a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec butyl group, or a tert butyl group.
- a methyl group or an ethyl group is preferred, and a methyl group is particularly preferred.
- the lower alkoxy group include linear or branched alkoxy groups having 1 to 6 carbon atoms such as methoxy group, ethoxy group, propoxy group, isopropoxy group, n -butoxy group, sec butoxy group, and tert butoxy group.
- R 2 is preferably a lower alkyl group, and most preferably a methyl group.
- the present invention also includes a pharmaceutically acceptable salt of the compound of the general formula (1).
- salts include salts with inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, etc .; acetate, trifluoroacetate, oxalic acid Salts with organic acids such as salt, fumarate, maleate, tartrate, mesylate and tosylate; salts with alkali metals such as sodium salt and rhodium salt; alkaline earth such as calcium salt Examples thereof include salts with similar metals, which can be obtained by reacting an inorganic acid or an organic acid according to a conventional method.
- the compound (1) of the present invention has an optical isomer based on an asymmetric carbon atom.
- the present invention Isolated of these various isomers and mixtures of these isomers.
- the compound (1) of the present invention includes hydrates and various solvates. Furthermore, the compounds of the present invention include all of their crystal forms.
- Hydrogensulfate 2 (3 Gua-Dinocarboro 2—methyl-6, 7, 8, 9-tetrahydro-5H cyclohepta [b] pyridine 9-methylmethyloxycarbolamino) ethyl
- hydrogensulfate 2 [2— (3-Guano-dinocarboru 2-methyl-6,7,8,9-tetrahydro-5H-cyclohepta [b] pyridine 9-ylmethyloxycarbolamino) ethoxy] ethyl,
- Hydrogen sulfate 17 (3-Guano-dinocarbo-ru 2-Methyl-6, 7, 8, 9-Tetrahydro —5H-cyclohepta [b] Pyridine-9-methylmethyloxy-carboamino) —3, 6, 9 , 12, 15 1 pentaxaheptadecane,
- Step 1 will be described below.
- This step is a step for producing the compound represented by the general formula (la) by subjecting the primary hydroxyl group of the compound represented by the general formula (2) to a sulfate esterification reaction.
- the compound of the general formula (2) is pyridine, triethylamine, in an organic solvent such as black mouth form, dichloromethane, dimethylformamide (hereinafter abbreviated as DMF), jetyl ether or tetrahydrofuran (hereinafter abbreviated as THF) or without solvent.
- a sulfuric acid esterifying agent such as chlorosulfonic acid, concentrated sulfuric acid, sulfur trioxide, sulfur trioxide'pyridine complex is used, and 0 to
- the compound of the general formula (la) can be obtained by reacting at a temperature of 40 ° C. for 1 to 24 hours.
- the compound of the general formula (2) can be obtained by carrying out a heating reaction using guanidine from a cycloalkaline [b] pyridine derivative, for example, according to the method disclosed in WO98Z39300.
- R 2 has the same meaning as described above, R 3 represents a lower alkyl group, and R 4 represents a halogen atom.
- This step is a step for producing a compound represented by the general formula (4) by converting the hydroxyl group of the compound represented by the general formula (3) into a leaving group R 4 . That is, the compound of the general formula (3) is synthesized in an organic solvent such as chloroform, formaldehyde, dichloromethane, benzene, toluene, acetonitrile, DMF, jetyl ether or THF, or without solvent, in pyridine, triethylamine, dimethyl-lin or dimethylamine.
- an organic solvent such as chloroform, formaldehyde, dichloromethane, benzene, toluene, acetonitrile, DMF, jetyl ether or THF, or without solvent, in pyridine, triethylamine, dimethyl-lin or dimethylamine.
- a compound of the general formula (4) can be obtained by reacting at a temperature of 20 ° C. to the boiling point for 1 to 48 hours using an agent.
- the compound of the general formula (3) can be obtained by conducting a heating reaction using paraformaldehyde in a sealed tube of a cycloalka [b] pyridine derivative according to the method disclosed in WO98Z39300, for example.
- This step is a step of producing the compound represented by the general formula (5) by converting the leaving group R 4 of the compound of the general formula (4) into a sulfonic acid. That is, the compound of the general formula (4) is mixed with sodium sulfite or ammonium sulfite in a hydrophilic solvent such as methanol, ethanol, n-propanol, acetone, DMF, a mixed solvent with water, or in water. Etc.
- a compound of the general formula (5) can be obtained by reacting at a temperature between room temperature and boiling point for 1 to 48 hours using a sulfonating agent.
- This step is a step for producing the compound represented by the general formula (lb) by converting the ester group of the compound represented by the general formula (5) into a guanidinocarbonyl group. That is, the compound of the general formula (6) is used in an organic solvent such as methanol, ethanol, DMF, jetyl ether, THF, or 1,4 dioxane, or without solvent, using guanidine at 0-100 ° C.
- the compound of the general formula (lb) can be obtained by reacting at a temperature for 1 to 24 hours.
- R 1 is —OCONH— (CH 2 CH 2 O) —SO 2 H or the following formula
- the compound of the general formula (1) of the present invention can be produced, for example, according to the reaction formula shown below.
- R 2 , R 3 and n are as defined above, and E is — (CH 2 CH 2 O) — or
- R 5 represents a leaving group
- R 6 represents a hydrogen atom or a hydroxyl-protecting group
- R 7 represents a sulfo group
- Examples of the leaving group for R 5 include a 4-trophenoxy group and an imidazolyl group.
- Examples of the protecting group for R 6 include a trisubstituted silyl group and a benzyl group. If R 6 is a hydrogen atom, step 8 is not performed. Steps 5 to 9 will be described below.
- This step is a step for producing the compound represented by the general formula (6) by subjecting the primary hydroxyl group of the compound represented by the general formula (3) to an active esterification reaction. That is, the compound of the general formula (3) is added to an organic solvent such as chloroform, formaldehyde, dichloromethane, DMF, jetyl ether, or THF, or without solvent, such as pyridine, triethylamine, dimethylaminoline, or dimethylaminopyridine. In the presence or absence of a grade amine, using an active esterifying agent such as 4-nitrophenol 1, 1, -carbodiimidazole, etc. at a temperature of 0 to 40 ° C for 1 to 24 hours By reacting, the compound of the general formula (6) can be obtained.
- an organic solvent such as chloroform, formaldehyde, dichloromethane, DMF, jetyl ether, or THF
- solvent such as pyridine, triethylamine, dimethylaminoline, or di
- This step is a step for producing a compound represented by the general formula (8) by reacting an active ester compound represented by the general formula (6) with a primary amine represented by the general formula (7). That is, the compound of the general formula (6) and the primary amine represented by the general formula (7) are mixed with pyridine, triethylamine in an organic solvent such as black mouth form, dichloromethane, DMF, jetyl ether or THF or without solvent. In the presence or absence of tertiary amine such as dimethylamino- or dimethylaminopyridine, the compound of general formula (8) is obtained by reaction at a temperature of 0-40 ° C for 1-24 hours. be able to.
- Tetrahedron Letters, 2001, 42, p. 3819 It can be obtained from an ethylene glycol derivative according to the method disclosed in 3822.
- E is the following formula
- the hydroxyl group of isomannide is converted to a leaving group and then subjected to a nucleophilic substitution reaction with aqueous ammonia.
- This step is a step for producing the compound represented by the general formula (9) by converting the ester group of the compound represented by the general formula (8) into a guanidinocarbonyl group. That is, the compound of the general formula (8) is used in an organic solvent such as methanol, ethanol, DMF, jetyl ether, THF or 1,4 dioxane, or without solvent, using guanidine at 0-100 ° C.
- the compound of the general formula (9) can be obtained by reacting at a temperature for 1 to 24 hours.
- This step is a step for producing the compound represented by the general formula (10) by deprotecting the protecting group for the hydroxyl group of R 6 of the compound represented by the general formula (9).
- the protecting group is a trisubstituted silyl group
- the compound of the general formula (9) is converted to 0 to 40 ° in an organic solvent such as THF using hydrogen fluoride or tetrabutylammonium fluoride.
- an organic solvent such as THF using hydrogen fluoride or tetrabutylammonium fluoride.
- a compound of the general formula (10) can be obtained.
- the protecting group is a benzyl group
- a well-known method such as a catalytic reduction method can be used.
- the compound of the general formula (9) is mixed with an organic solvent such as methanol, ethanol, 1,4 dioxane or DMF, radium carbon, palladium black, salt tris (triphenylphosphine) rhodium or acid platinum.
- the general formula (10) can be obtained by performing a reaction for 1 to 24 hours at a temperature of 0 to 100 ° C. under normal pressure or medium pressure hydrogen pressure using a transition metal catalyst such as
- this step the hydroxyl group of the compound represented by the general formula (10) is subjected to a sulfuric acid ester reaction.
- a sulfuric acid ester reaction is a process for producing a compound represented by the general formula (lc). That is, the compound represented by the general formula (10) is added to an organic solvent such as chloroform, formaldehyde, dichloromethane, DMF, jetyl ether or THF or without solvent, such as pyridine, triethylamine, dimethylamino- or dimethylaminopyridine.
- R 1 is — OCONH— (CH 2 CH 2 O) —SO 2 H or the following formula:
- the compound of the general formula (1) of the present invention can be produced according to the following reaction formula.
- R 9 represents a protecting group for gua-dino group
- J represents —NH— (CH 2 CH 2 O) H or
- Examples of the protecting group for R 9 include a tert-butoxycarbonyl (hereinafter abbreviated as Boc) group and a benzyloxycarbonyl (hereinafter abbreviated as Z) group.
- Boc tert-butoxycarbonyl
- Z benzyloxycarbonyl
- This step is a step for producing the compound represented by the general formula (11) by protecting the guanidino group of the compound represented by the general formula (2) with, for example, a Boc group or a Z group.
- it can be carried out by a known method.
- protecting group 3 ⁇ 4oc group use di-tert-butyl dicarbonate or 2- (tert-butoxycarbo-loximino) 2-phenylacetonitrile, etc., in a solvent such as 1,4 dioxane, DMF, water or mixed solvent
- the general formula (11) can be obtained by reacting at a temperature of 0 to 80 ° C.
- This step is a step for producing the compound represented by the general formula (12) by subjecting the primary hydroxyl group of the compound represented by the general formula (11) to an active esterification reaction.
- the compound of general formula (11) is a tertiary compound such as pyridine, triethylamine, dimethylamine, dimethylaminopyridine or the like in an organic solvent such as chloroform, dichloromethane, DMF, jetyl ether or THF or without solvent. Black mouth carbonate 4-nitrite in the presence or absence of amine
- the compound of general formula (12) is obtained by reacting for 1 to 24 hours at a temperature of 0 to 40 ° C using an active esterifying agent such as oral ferrule 1, 1, -carbodiimidazole. be able to.
- This step is a step of producing a compound represented by the general formula (14) by reacting an active ester compound represented by the general formula (12) with an amine represented by the general formula (13) or a salt thereof. is there . That is, the compound represented by the general formula (12) and the amine represented by the general formula (13) or a salt thereof in an organic solvent such as chloroform, dichloromethane, DMF, jetyl ether, or THF, or in the absence of solvent, pyridine, triethyla A compound of the general formula (14) is obtained by reacting at a temperature of 0 to 40 ° C. for 1 to 24 hours in the presence or absence of a tertiary amine such as min, dimethylamine or dimethylaminopyridine. Can do.
- a tertiary amine such as min, dimethylamine or dimethylaminopyridine.
- the compound of the general formula (13) or a salt thereof is, for example, «J-NH— (CH 2 CH 3 O) H
- This step is a step for producing a compound represented by the general formula (15) by deprotecting the protecting group of the compound represented by the general formula (14).
- Deprotection can be performed by a known method.
- the compound of the general formula (14) is dissolved in an organic solvent such as methanol, ethanol, 1,4-dioxane or ethyl acetate, under acidic conditions such as hydrogen chloride or trifluoroacetic acid.
- the compound of the general formula (15) can be obtained by reacting at a temperature of 0 to 40 ° C. for 1 to 24 hours.
- a well-known method such as a catalytic reduction method can be used.
- the compound of the general formula (14) is dissolved in an organic solvent such as methanol, ethanol, 1,4 dioxane or DMF, palladium carbon, palladium black, salt tris (trifluorophosphine) rhodium, platinum oxide, etc.
- the general formula (15) can be obtained by reacting at a temperature of 0 to L00 ° C under normal pressure or medium pressure hydrogen pressure for 1 to 24 hours.
- This step is a step of producing the compound represented by the general formula (Id) by subjecting the hydroxyl group of the compound represented by the general formula (15) to a sulfate ester reaction. That is, the compound of the general formula (15) is added to an organic solvent such as chloroform, formaldehyde, dichloromethane, DMF, jetyl ether or THF or without solvent, such as pyridine, triethylamine, dimethylamino-dimethyl or dimethylaminopyridine.
- an organic solvent such as chloroform, formaldehyde, dichloromethane, DMF, jetyl ether or THF or without solvent, such as pyridine, triethylamine, dimethylamino-dimethyl or dimethylaminopyridine.
- the compound of the general formula (1) thus produced can be isolated and purified by conventional means such as recrystallization and column chromatography.
- the cyclohepta [b] pyridine 3 carbonyldadiyne derivative represented by the general formula (1) of the present invention or a pharmaceutically acceptable salt thereof is used in vitro and as described below as test examples. It exhibits excellent NHE inhibitory action in vivo and extremely low toxic effects on the central nervous system. Therefore, the cyclohepta [b] pyridine 3 carbonyldazine derivative represented by the general formula (1) of the present invention or a pharmaceutically acceptable salt thereof is used in various diseases caused by stimulation of drugs, particularly NHE. For example, hypertension, arrhythmia, angina pectoris, cardiac hypertrophy, diabetes, ischemia or ischemia-reperfusion organ damage (e.g.
- myocardial ischemia reperfusion acute renal failure, organ transplantation, percutaneous coronary lumen expansion Disorders caused by surgery (PTCA), cerebral ischemic disorders (eg disorders associated with cerebral infarction, disorders that occur as a sequelae after stroke, cerebral edema, etc.), cell overgrowth (eg fibroblast proliferation, smooth muscle cells) Diseases caused by proliferation, mesangial cell proliferation, etc.
- PTCA percutaneous coronary lumen expansion Disorders caused by surgery
- cerebral ischemic disorders eg disorders associated with cerebral infarction, disorders that occur as a sequelae after stroke, cerebral edema, etc.
- cell overgrowth eg fibroblast proliferation, smooth muscle cells
- Atherosclerosis pulmonary fibrosis, liver fibrosis, renal fibrosis, renal glomeruli
- systemic sclerosis organ enlargement, prostatic hypertrophy, diabetic complications, restenosis after PTCA
- restenosis due to coronary endothelial thickening after percutaneous coronary angioplasty diseases caused by vascular endothelial cell disorders such as arteriosclerosis, etc. It is useful as a therapeutic or preventive agent for
- the compound of the general formula (1) or a salt thereof of the present invention when used as a medicine, it can be administered orally or parenterally.
- the dosage form for administration includes pharmaceutically acceptable additives such as excipients, binders, buffers, thickeners, stabilizers, emulsifiers, dispersants, suspending agents, preservatives, etc. And can be formulated by a usual method.
- Examples of the preparation for oral administration include tablets (including sugar-coated tablets and film-coated tablets), pills, granules, powders, capsules (including soft capsules), syrups, emulsions and suspensions.
- This preparation for oral administration can be produced according to a known method by blending with an additive carotenoid usually used in the pharmaceutical field.
- additives include excipients such as lactose, mannitol and anhydrous calcium hydrogen phosphate; binders such as hydroxypropylcellulose, methylcellulose, and polyvinylpyrrolidone; disintegrants such as starch and carboxymethylcellulose; Examples thereof include lubricants such as magnesium stearate and talc.
- injection can be administered as an injection, a rectal preparation, a topical preparation, and the like, and an injection is preferred.
- examples of the injection include a sterile solution or suspension. These injections are produced, for example, by dissolving or suspending the compound of the general formula (1) or a pharmaceutically acceptable salt thereof in water for injection in JP. If necessary, isotonic agents such as sodium chloride sodium; buffering agents such as sodium dihydrogen phosphate and sodium monohydrogen phosphate
- a solubilizing agent may be blended.
- it can be used as an injectable preparation (powder-filled, freeze-dried) injection, and in this case, it can be produced by a usual method by adding excipients such as mannitol and lactose.
- Rectal administration preparations include suppositories.
- a suppository is produced by, for example, dissolving or suspending a compound of the general formula (1) or a pharmaceutically acceptable salt thereof in a base such as cacao butter or macrogol and pouring it into a mold.
- a solution or cream can be placed in a container for injection to form a rectal preparation.
- Topical preparations include solutions, eye drops, creams, ointments, gel preparations, sprays, powders, etc. Can be mentioned.
- For liquids add the compound of general formula (1) or a pharmaceutically acceptable salt thereof to water, and add stabilizers, solubilizers, thickeners, dispersants, suspending agents, etc. as necessary.
- This thickener gelatin, sodium hyaluronate, high molecular dextran, sodium alginate, sodium chondroitin sulfate, etc. can be used.
- Eye drops can be produced by adding a preservative in addition to a buffer, a pH adjuster, and an isotonic agent.
- Creams and ointments can be manufactured using an aqueous or oily base such as water, liquid paraffin, vegetable oil (peanut oil, castor oil, etc.), macrogol and the like.
- Gel preparations are prepared by known methods using gelatin, pectin, strength ragenan, agar, tragacanth, alginate, cellulose ether (methylcellulose, sodium carboxymethylcellulose, etc.), pectin derivatives, polyacrylates, polymetatalites. It can be produced by using rate, polybum alcohol and polybylpyrrolidone.
- the spray can be produced by dissolving or suspending the compound of the general formula (1) or a pharmaceutically acceptable salt thereof in water or the like and then putting it in a spray container.
- the compound of the general formula (1) or a pharmaceutically acceptable salt thereof can be used as it is, but it can be prepared by mixing with an appropriate excipient.
- the daily dose of the compound represented by the general formula (1) may vary depending on the patient's symptoms, body weight, age, type of compound, route of administration, etc.
- Application amount ⁇ to about 0.01 to L: OOOmg force is appropriate, about 0.1 to 300 mg force ⁇ preferred! / ⁇ .
- OOOmg force is appropriate, about 0.1 to 300 mg force ⁇ preferred! / ⁇ .
- These doses can be appropriately increased or decreased depending on the patient's symptoms, body weight, age and the like.
- Reference compound 1 29.9 g, 214 mmoL
- 3-amino crotonic acid methinole 25. lg, 218 mmoL
- acetic acid 30 mL
- the solvent was removed under reduced pressure, and neutralized with a saturated aqueous sodium carbonate solution under ice cooling.
- the mixture was extracted twice with ethyl acetate, washed with water, saturated aqueous sodium hydrogen carbonate solution and saturated brine, and dried over anhydrous magnesium sulfate.
- Reference compound 2 (30. Og, 137 mmoL) and paraformaldehyde (24.6 g) were placed in an iron sealed tube and stirred at 120 ° C. for 24 hours.
- the reaction solution was extracted with 10% (vZv) hydrochloric acid and washed with ether.
- 40% (wZv) aqueous sodium hydroxide solution to the aqueous layer under ice cooling.
- it was adjusted to pHIO and extracted twice with black mouth form.
- the organic layer was washed with water and saturated brine, and dried over anhydrous sodium sulfate.
- Reference Example 6-3 Method 6-3—Methoxycarbonyl 2-methyl-6.7.8.9-tetrahydro-5H cyclohepta “bl pyridine 9-inoremethanesnorephonic acid (reference compound 6)
- ImoLZL hydrochloric acid was added little by little to adjust the pH to 2-3 and washed with black mouth form.
- Chromium carbonate 4 Nitrophenol (1.21 g, 6. OmmoL) in dichloromethane (7.5 mL) was dissolved in an ice bath with reference compound 3 (1.25 g, 5. OmmoL) and pyridine (0.8 mL, 10 mmoL). ) In dichloromethane (2.5 mL) was added and stirred at the same temperature for 2 hours. The reaction mixture was diluted with chloroform, washed with saturated aqueous sodium hydrogen carbonate solution and saturated brine, and dried over anhydrous sodium sulfate.
- Reference compound ll (541 mg, 1. OmmoL) was added to a solution of 2- (2-aminoethoxy) ethanol (0.10 mL, 1. OmmoL) and triethylamine (0.42 mL, 3. OmmoL) in DMF (lOmL) under an argon atmosphere.
- DMF liquid-free ethanol
- lOmL dimethyl sulfoxide
- the solvent was distilled off, and the residue was dissolved in black mouth form and washed with 1% (WZV) aqueous sodium hydroxide solution, saturated aqueous sodium chloride solution and saturated brine.
- Reference compound 4 (553mg, 2. OmmoL) in DMF (lOmL) suspension in an ice bath with dibenzyl N, N, -diisopropyl Phosphoramidite (1. OmL, 3. OmmoL) and 1H-tetrazole (322 mg, 4.6 mmoL) were added, and the mixture was stirred at room temperature for 2 hours, and then m-cloperbenzoic acid (70 ° C at -78 ° C). %; 740 mg, 3.
- Example 4-3 Guanidinocarbonyl 2 methyl-6.7.8.9-tetrahydro-5H-cyclohepta
- bl pyridine 9-inoremethansenorephonic acid sodium salt present compound 4
- present compound 3 (1.90 g, 5.58 mmoL)
- the title compound (1.67 g, 83%) was obtained as a colorless powder in the same manner as in Example 2.
- Distilled water (3 mL) is compounded with Compound 5 (133 mg, 0.30 mmoL) as a suspension, and 28% (wZv) sodium methoxide Z methanol solution (585 / zL, 0.30 mmoL) is added to room temperature. And stirred overnight. After evaporation of the solvent, the title compound (130 mg, 93%) was obtained as a colorless powder by drying under reduced pressure.
- Example 10 “Sulfuric acid 17— (3 guanidinocarbonyl 2 methyl-6.7.8.9-tetrahydro 5H cyclohepta“ b1 pyridine 9-methylmethyloxycarbonylamino ”) 3. 6.9.12.15 pentaoxaheptadecane 1-yl sodium salt (present compound 10) The title compound (68.2 mg, 69%) was obtained as a colorless amorphous form from the present compound 9 (95.7 mg, 0.14 mmoL) in the same manner as in Example 6.
- the title compound (195 mg, 83%) was obtained as a colorless powder.
- the compound represented by the general formula (1) of the present invention is obtained by converting the hydroxyl group on the 9-position methyl group of 9-hydroxymethyl-cyclohepta [b] pyridine 3-carbol-azine derivative into a specific substituent. It has a structure.
- the following test examples of representative compounds of the present invention were compared with the corresponding 9 hydroxymethyl cyclohepta [b] pyridine 3-carbonylguanidine derivatives and NHE inhibitory effects and central nervous system toxic effects. And evaluated. Further, for comparison with the present invention, in the general formula (I) of the present invention, I ⁇ prepared by introducing a phosphoric acid group instead of the group represented by R 1, I ⁇ prepared by changing the substitution site of R 1 Were also evaluated in the same way.
- Sulfuric acid 17 (3-Guano-dinocarboro 2-methyl-6, 7, 8, 9-tetrahydro-5H-cyclohepta [b] pyridine-9-ylmethyloxycarbolamino) —3, 6, 9, 12, 15 Pentaoxaheptadecane 1-yl sodium salt (Compound 10 of this application) Hydrogen sulfate 2 Deoxy—1, 4: 3, 6 Dianhydro 2— (3 Gua-dinocarbon —2—Methinore 6, 7, 8 , 9-Tetrahydro-5H cyclohepta [b] Pyridine 9-ylmethyoxycarboxy-lamino) D Glucitol 5-yl (Compound 12) Phosphoric acid 3 Gua-dinocarboro 2—Methyl 6, 7, 8, 9 —Tetrahydro-5H cis Hepta [b] pyridine— 9-methylmethyl disodium salt (Reference compound 20)
- test results show the concentration (IC value) at which the inhibitory activity is 50% depending on the test compound.
- Table 1 shows the IC values of NHE inhibitory activity of these test compounds.
- Reference compound 20 6. 6 2 X 1 0— " 7 M Reference compound 22> 1. 0 0 X 1 0- _ 4 M
- the snare was tightened for localized myocardial ischemia. Furthermore, the compound is administered intravenously in 1 minute from the 4th minute of myocardial ischemia, and the arrhythmia that appears after the reperfusion is performed by loosening the snare in the 5th minute of ischemia using the arrhythmia analyzer (manufactured by Softron). By recording and analyzing, the antiarrhythmic action of the compounds was evaluated.
- the test compound was dissolved in physiological saline at a concentration of 3.62 mmol ZL, and lmLZkg was administered to 4 to 5 patients in each group. A physiological saline was administered to the control group.
- Vf Ventricular fibrillation
- Table 2 shows the Vf frequency, Vf cumulative duration and mortality for each test compound.
- the compound of the present invention showed a high NHE inhibitory action in vitro and in vivo. in vit In ro, a slight decrease in activity was seen compared to the control compound, but the NHE inhibitory activity was strong.
- the activity of the reference compounds 22 and 23 in which a sulfooxy group was introduced at the 5-position or 2-position of the cyclohepta [b] pyridin ring was significantly reduced.
- the compounds of the present invention significantly shortened Vf cumulative duration and reduced mortality, and were more than equivalent to control compounds in effectiveness.
- the compound represented by the general formula (1) of the present invention has a structure in which the 9-position hydroxyl group of 9-hydroxymethyl-cyclohepta [b] pyridine 3-carbol-azine derivative is converted to a specific substituent. Is metabolized in vivo, and its specific substituent is eliminated, resulting in the original 9-hydroxymethyl-cyclohepta [b] pyridine 3-carbo-guanidine derivative, which is toxic to the central nervous system. There is a concern to cause. Therefore, the compounds of the examples of the present invention were administered in vivo, and it was evaluated whether or not the corresponding 9-hydroxymethyl compound control compound was produced.
- mice Male SD rats (7 weeks of age) were administered lmgZkg of the control compound or the equivalent of the present compound 2, 4, 6, 7, and 12 or reference compound 20 in the tail vein as a calculated amount excluding salt. After administration, blood was collected approximately 0.2 mL at 5, 15, 30, 60, and 120 minutes, and centrifuged at 4 ° C and 15000 rpm for 15 minutes to separate the supernatant plasma. Control compound concentrations in plasma were measured by LCZMSZMS. The measurement results are +++ when the plasma concentration of the detected control compound is 200 ngZmL or more, +++ when lOOngZmL or more, less than 200 ngZmL, + when it is 20 ngZmL or more, and less than lOOngZmL. Table 3 shows.
- mice Each were given intraperitoneal administration of 300 mgZkg of the control compound or the equivalent of the present compound 2, 4, 6, 7 and 12 equivalent to the same amount once a day for 2 days, excluding salt.
- a tissue examination was performed.
- the control compound, the present compounds 2, 4 and 6 were suspended in 0.5% tragacanth rubber solution
- the present compound 7 was suspended in 10% DMSO containing 0.5% tragacanth rubber solution
- the present compound 12 was suspended in olive oil.
- pathological examination in order to investigate further the central neurotoxicity, whole body perfusion was fixed with 4% neutral phosphate buffered formaldehyde fixative solution using a liquid pump under anesthesia with pentobarbital sodium, and the brain was examined. .
- mice Male SD rats (6 weeks old) were administered with the control compound or Compound 2 of the present invention via the tail vein so as to be 50 mgZkg, respectively. After administration, whole blood was collected from the abdominal aorta over time under ether anesthesia, and brain tissue was immediately removed. The brain tissue was lightly washed with blood with saline and then frozen in liquid nitrogen and stored at -30 ° C until analysis. The blood was centrifuged at 15,000 rpm for 15 minutes at 4 ° C, and the supernatant plasma was separated and stored at -30 ° C until analysis. The brain tissue was naturally thawed, weighed, weighed 5 times the wet weight of distilled water, and prepared a suspension with a Polytron homogenizer. LCZMSZMS was used to measure test compound concentrations in plasma and brain tissue. Drug transfer into the brain was calculated by dividing the brain tissue drug concentration by the plasma concentration at the same time. Table 4 shows the test results.
- Compound 2 of the present invention has reduced migration to brain tissue. This supported the reduction of toxic effects on the central nervous system.
- 50 mg of the present compound 2 and 900 mg of sodium chloride sodium salt were dissolved in 90 mL of water for injection, adjusted to pH 7.0 with ImmolZL hydrochloric acid, and further made up to a total volume of lOOmL using water for injection.
- the solution was aseptically filtered, and 2 mL each was filled into a glass ampoule to produce an injection (solution) containing 1 mg of the present compound 2 in one tube.
- Whitebuzole H-15 was heated and melted, and to this was added Compound 2 of this application so as to be lOmgZmL, and mixed uniformly. 2 mL of this was poured into a plastic container for suppositories and cooled to produce a suppository containing 20 mg of the present compound 2 in one container.
- This solution was aseptically filtered, and 5 mL each was filled into a polypropylene eye drop container to produce an eye drop having a concentration of Compound 2 of 0.05%.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006800047317A CN101119971B (zh) | 2005-02-16 | 2006-02-16 | 环庚[b]吡啶-3-羰基胍衍生物及含有该衍生物的医药品 |
DK06713854.5T DK1849774T3 (da) | 2005-02-16 | 2006-02-16 | Cyclohepta(b)pyridin-3-carbonylguanidinderivat og farmaceutisk produkt indeholdende samme |
CA2598988A CA2598988C (en) | 2005-02-16 | 2006-02-16 | Cyclohepta[b]pyridine-3-carbonylguanidine derivative and pharmaceutical product containing the same as nhe inhibitors |
AU2006215084A AU2006215084B2 (en) | 2005-02-16 | 2006-02-16 | Cyclohepta(b)pyridine-3-carbonylguanidine derivative and pharmaceutical product containing same |
EP06713854A EP1849774B1 (en) | 2005-02-16 | 2006-02-16 | CYCLOHEPTA(b)PYRIDINE-3-CARBONYLGUANIDINE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME |
KR1020077018533A KR101255868B1 (ko) | 2005-02-16 | 2006-02-16 | 시클로헵타[b]피리딘-3-카르보닐구아니딘 유도체 및그것을 함유하는 의약품 |
US11/816,420 US7875625B2 (en) | 2005-02-16 | 2006-02-16 | Cyclohepta[b]pyridine-3-carbonylguanidine derivative and pharmaceutical product containing same |
JP2007503693A JP4826983B2 (ja) | 2005-02-16 | 2006-02-16 | シクロヘプタ[b]ピリジン−3−カルボニルグアニジン誘導体およびそれを含有する医薬品 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005038780 | 2005-02-16 | ||
JP2005-038780 | 2005-02-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006088080A1 true WO2006088080A1 (ja) | 2006-08-24 |
Family
ID=36916481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/302713 WO2006088080A1 (ja) | 2005-02-16 | 2006-02-16 | シクロヘプタ[b]ピリジン-3-カルボニルグアニジン誘導体およびそれを含有する医薬品 |
Country Status (10)
Country | Link |
---|---|
US (1) | US7875625B2 (ja) |
EP (1) | EP1849774B1 (ja) |
JP (1) | JP4826983B2 (ja) |
KR (1) | KR101255868B1 (ja) |
CN (1) | CN101119971B (ja) |
AU (1) | AU2006215084B2 (ja) |
CA (1) | CA2598988C (ja) |
DK (1) | DK1849774T3 (ja) |
ES (1) | ES2365531T3 (ja) |
WO (1) | WO2006088080A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009119086A1 (ja) * | 2008-03-26 | 2009-10-01 | トーアエイヨー株式会社 | 9-ヒドロキシメチル-シクロヘプタ[b]ピリジン-3-カルボン酸エステル誘導体の製造方法 |
JP2011519877A (ja) * | 2008-05-09 | 2011-07-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | インスリン抵抗性およびβ−細胞機能障害に関連する疾患を治療するためのリメポリドを含む医薬組成物 |
JP2018534343A (ja) * | 2015-09-08 | 2018-11-22 | オーピーツー ドラッグス | ミトコンドリアの活性酸素種(ros)産生に関連する疾患の治療のための化合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08208602A (ja) * | 1994-10-18 | 1996-08-13 | Sumitomo Pharmaceut Co Ltd | インドロイルグアニジン誘導体 |
WO1998039300A1 (fr) * | 1997-03-06 | 1998-09-11 | Toa Eiyo Ltd. | DERIVES DE CYCLOALCA[b]PYRIDINE-3-CARBONYLGUANIDINE, LEUR PROCEDE DE PRODUCTION ET MEDICAMENTS LES CONTENANT |
JPH11286454A (ja) * | 1998-01-29 | 1999-10-19 | Sumitomo Pharmaceut Co Ltd | 虚血性脳血管障害の治療剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE59302959D1 (de) | 1992-02-15 | 1996-07-25 | Hoechst Ag | 3,5-Substituierte Benzoylguanidine, mit antiarrythmischer Wirkung und inhibierender Wirkung auf die Proliferationen von Zellen |
DE4430861A1 (de) | 1994-08-31 | 1996-03-07 | Merck Patent Gmbh | Heterocyclyl-benzoylguanidine |
CA2160600A1 (en) * | 1994-10-18 | 1996-04-19 | Masahumi Kitano | Indoloylguanidine derivatives |
JP2000191641A (ja) | 1998-02-20 | 2000-07-11 | Takeda Chem Ind Ltd | アミノグアニジンヒドラゾン誘導体、その製法及び剤 |
US6350749B1 (en) | 1998-02-20 | 2002-02-26 | Takeda Chemical Industries, Ltd. | Aminoguanidine hydrazone derivatives, process for producing the same and drugs thereof |
WO2001044186A1 (fr) | 1999-12-16 | 2001-06-21 | Sumitomo Pharmaceuticals Company, Limited | Derives de guanidine substitues |
JP4317233B2 (ja) | 2007-02-26 | 2009-08-19 | 新生精機株式会社 | 建築用シャッターの急降下停止装置 |
-
2006
- 2006-02-16 CN CN2006800047317A patent/CN101119971B/zh not_active Expired - Fee Related
- 2006-02-16 US US11/816,420 patent/US7875625B2/en not_active Expired - Fee Related
- 2006-02-16 WO PCT/JP2006/302713 patent/WO2006088080A1/ja active Application Filing
- 2006-02-16 KR KR1020077018533A patent/KR101255868B1/ko active IP Right Grant
- 2006-02-16 CA CA2598988A patent/CA2598988C/en not_active Expired - Fee Related
- 2006-02-16 EP EP06713854A patent/EP1849774B1/en not_active Not-in-force
- 2006-02-16 JP JP2007503693A patent/JP4826983B2/ja not_active Expired - Fee Related
- 2006-02-16 ES ES06713854T patent/ES2365531T3/es active Active
- 2006-02-16 DK DK06713854.5T patent/DK1849774T3/da active
- 2006-02-16 AU AU2006215084A patent/AU2006215084B2/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08208602A (ja) * | 1994-10-18 | 1996-08-13 | Sumitomo Pharmaceut Co Ltd | インドロイルグアニジン誘導体 |
WO1998039300A1 (fr) * | 1997-03-06 | 1998-09-11 | Toa Eiyo Ltd. | DERIVES DE CYCLOALCA[b]PYRIDINE-3-CARBONYLGUANIDINE, LEUR PROCEDE DE PRODUCTION ET MEDICAMENTS LES CONTENANT |
JPH11286454A (ja) * | 1998-01-29 | 1999-10-19 | Sumitomo Pharmaceut Co Ltd | 虚血性脳血管障害の治療剤 |
Non-Patent Citations (2)
Title |
---|
See also references of EP1849774A4 * |
YAMAMOTO T. ET AL.: "Quantiative structure-activity relationship study of N-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carbonyl)guanidines as potent Na/H exchange inhibitors", CHEM. PHARM. BULL., vol. 48, no. 6, June 2000 (2000-06-01), TOKYO, pages 843 - 849, XP002997199 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009119086A1 (ja) * | 2008-03-26 | 2009-10-01 | トーアエイヨー株式会社 | 9-ヒドロキシメチル-シクロヘプタ[b]ピリジン-3-カルボン酸エステル誘導体の製造方法 |
JP5424272B2 (ja) * | 2008-03-26 | 2014-02-26 | トーアエイヨー株式会社 | 9−ヒドロキシメチル−シクロヘプタ[b]ピリジン−3−カルボン酸エステル誘導体の製造方法 |
JP2011519877A (ja) * | 2008-05-09 | 2011-07-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | インスリン抵抗性およびβ−細胞機能障害に関連する疾患を治療するためのリメポリドを含む医薬組成物 |
US10292949B2 (en) | 2008-05-09 | 2019-05-21 | Meck Patent Gmbh | Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and β-cell dysfunction |
JP2018534343A (ja) * | 2015-09-08 | 2018-11-22 | オーピーツー ドラッグス | ミトコンドリアの活性酸素種(ros)産生に関連する疾患の治療のための化合物 |
Also Published As
Publication number | Publication date |
---|---|
KR20070107039A (ko) | 2007-11-06 |
CN101119971A (zh) | 2008-02-06 |
CA2598988C (en) | 2013-06-25 |
AU2006215084A1 (en) | 2006-08-24 |
DK1849774T3 (da) | 2011-10-10 |
JP4826983B2 (ja) | 2011-11-30 |
US7875625B2 (en) | 2011-01-25 |
CA2598988A1 (en) | 2006-08-24 |
EP1849774A4 (en) | 2009-11-25 |
EP1849774A1 (en) | 2007-10-31 |
CN101119971B (zh) | 2010-09-08 |
JPWO2006088080A1 (ja) | 2008-07-03 |
EP1849774B1 (en) | 2011-06-29 |
KR101255868B1 (ko) | 2013-04-23 |
US20090012114A1 (en) | 2009-01-08 |
AU2006215084B2 (en) | 2011-03-24 |
ES2365531T3 (es) | 2011-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8252779B2 (en) | Analogs of benzoquinone-containing ansamycins and methods of use thereof | |
DE60008372T2 (de) | Pharmazeutisch aktive verbindungen | |
US20060019941A1 (en) | Analogs of benzoquinone-containing ansamycins and methods of use thereof | |
WO2013184698A1 (en) | Solid forms of an antiviral compound | |
CN107382966B (zh) | 一类荜茇酰胺-川芎嗪杂合物、制备方法及医药用途 | |
EP2278965B1 (de) | Substituierte pyrazolamide und ihre verwendung | |
WO2006088080A1 (ja) | シクロヘプタ[b]ピリジン-3-カルボニルグアニジン誘導体およびそれを含有する医薬品 | |
JP2005527518A (ja) | 新規なカルコン(chalcone)誘導体とその使用 | |
US7507839B2 (en) | Therapeutic ion channel blocking agents and methods of use thereof | |
KR950001040B1 (ko) | 티오우레아 유도체 및 이를 함유하는 항균제 및 항궤양제 | |
CN106661060A (zh) | 菲罗啉膦酸类衍生物及其制备方法和应用 | |
US6117867A (en) | Substituted 6-R-1,3,4-thiadiazine-2-amines, the use thereof as anaesthetizing, cardiovascular and hypometabolic agents, and a pharmaceutical composition containing them | |
WO1998022443A1 (fr) | Derives de n-(imidazolylbutyle) benzenesulfonamide ayant une activite antithrombotique | |
JPH07188214A (ja) | 4−アミノキナゾリン誘導体、その製造方法およびそれを含有する医薬品 | |
WO1998042700A1 (fr) | Derives de n-(arginyl)benzenesulfonamide et leur utilisation comme agents antithrombotiques | |
JPH09110691A (ja) | 医薬組成物 | |
DE10135248A1 (de) | Tyrosinhydrazide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007503693 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6210/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2598988 Country of ref document: CA Ref document number: 200680004731.7 Country of ref document: CN Ref document number: 1020077018533 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006215084 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006713854 Country of ref document: EP Ref document number: 11816420 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006215084 Country of ref document: AU Date of ref document: 20060216 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006215084 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006713854 Country of ref document: EP |